And another autologous cellular therapy approved by the FDA. The door is wide open for OCC to walk through with a well trialled autlogous stem cell therapy, without the potency assay contentions of theapies like MSB's. The FDA has been showing itself very open to autologous cellular therapies. This is a defined change to pre-COVID.
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-mb-106-for-waldenstr-m-macroglobulinemia
I know investors are sick to death of hearing me and a "very excited" CEO, but the regulatory environment for ATI is much improved. Fingers, toes and any other extemities crossed that J&J sees this and joins OCC in a phase III partnership with OCC in the US, for a very now much more established and trodden path to approval in an autlogous cellular therapy.
Stem Cell Therapy advancements, page-301
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $54.39K | 137.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2298 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 193037 | 5 |
View Market Depth
| Last trade - 12.41pm 12/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |